Malignant mesotheliomas are highly aggressive cancers, usually linked to asbestos exposure. Most patients survive approximately one year after diagnosis, and only seven percent of patients make it past five years. If not diagnosed early, these cancers are extremely difficult to treat. However, early diagnosis is a challenge because patients may be unaware of previous asbestos exposure or present with non-specific symptoms.
Research is currently underway to better understand how these cancers develop, and how to improve survival. The American Cancer Society and National Cancer Institute are good resources for information on ongoing clinical trials and enrollment criteria. Treatment options being researched can broadly be classified into radiotherapy, light or photodynamic therapy, drug or chemotherapy, biotherapy and immunotherapy. While radiotherapy is palliative in chest pain and chest wall spread, it has no effect on survival. Photodynamic therapy is being evaluated for earlier stages of malignant pleural mesothelioma; it combines the injection of a drug that makes cancer cells sensitive to light with the use of light of a certain wavelength to kill these cells.
A promising clinical trial showed patients with advanced malignant mesothelioma lived for nearly three months longer than a comparison group when treated with a drug combination of Alimtaä and cisplatin. The University of Chicago’s Cancer Research Center is leading a trial that combines the anti-cancer drugs gemcitabine and cisplatin, which kill cancer cells, with the biological agent bevacizumab, which slows the growth of cancerous tissue and blood vessels in this tissue. Researchers at the National Cancer Institute have identified a protein called mesothelin that is present in higher levels in mesothelioma cancer cells than in surrounding normal tissue. This knowledge is being used in ongoing clinical trials of vaccines that could kill cancer cells by triggering an anti-mesothelin immune response, and is also being used to develop diagnostic tests to detect rising mesothelin levels in people with malignant mesothelioma.
Related Articles of Interest :
-
Malignant Peritoneal Mesothelioma
10 August 2010 8:30 PM |
No Comments
Malignant peritoneal mesothelioma is a cancer of the peritoneum, or tissue lining the abdomen and some of its organs. This lining tissue provides a small amount of lubricating fluid that allows organs in the gut to move and work properly. This cancer accounts for approximately...
-
Mesothelioma Treatment: What You Should Know
10 August 2010 8:30 PM |
No Comments
There are certain factors that influence the type of treatment a patient with malignant mesothelioma may undergo. These include the type of cancer, the location of the cancer, the stage or extent to which it has spread at diagnosis, whether the cancer can be removed...
-
Diffuse Malignant Pleural Mesothelioma
10 August 2010 8:30 PM |
No Comments
Diffuse malignant pleural mesothelioma, or DMM, is a rare but highly aggressive type of cancer. It occurs in the thin layer of tissue, the pleura, lining the chest cavity and lungs. Once diagnosed with DMM, most patients do not survive beyond one year. This cancer...
-
Malignant Mesothelioma
10 August 2010 8:30 PM |
No Comments
Malignant mesothelioma is a rare cancer in which malignant or cancerous cells form in the thin layers of tissue lining the human chest, heart or abdomen. When the cancer is in the chest, it affects the pleura or tissue lining the lungs and is called...
-
Malignant Pleural Mesothelioma
10 August 2010 8:30 PM |
No Comments
Malignant pleural mesothelioma is a cancer of the thin layer of tissue that lines the chest and lungs. It is a rare form of cancer that is mostly associated with exposure to asbestos. Malignant pleural mesothelioma is a fast-moving cancer with a median survival time...
-
Malignant Pleural Mesothelioma Survival Rate
10 August 2010 8:30 PM |
No Comments
Malignant pleural mesothelioma is the most common type of malignant mesothelioma. Many factors may be involved in determining the survival rate for this aggressive cancer; some are better understood than others. Estimates of median survival time range from one to two years; survival depends on...
-
Mesothelioma Diagnosis: An Introduction
10 August 2010 8:30 PM |
No Comments
A physician may suspect malignant mesothelioma in a patient who has symptoms suggesting this cancer and who reports a history of asbestos exposure. Careful medical examination may also reveal the presence of fluid in the pleural or abdominal cavity. Once malignant mesothelioma is suspected, a...
-
A Guide To Malignant Mesothelioma Diagnosis
10 August 2010 8:30 PM |
No Comments
The most critical form of mesothelioma is the malignant form. Known as malignant mesothelioma, the primary causal factor is asbestos infection. According to the US National Cancer Institute, “Malignant mesothelioma is a disease in which cancer (malignant) cells are found in the sac lining the...
-
A Guide To Malignant Peritoneal Mesothelioma
10 August 2010 8:30 PM |
No Comments
Malignant Peritoneal Mesothelioma is neoplasm arising from the serosal lining of the peritoneal and pericardial cavities. Primary tumors arising from the peritoneal mesothelioma are extremely rare. The accurate diagnosis of the diffuse peritoneal mesothelioma is important because it almost invariably has a fatal outcome. In...
-
Malignant Mesothelioma Diagnosis
10 August 2010 8:30 PM |
No Comments
When a patient has symptoms suggesting malignant mesothelioma, a doctor starts with imaging techniques to confirm a diagnosis. X-rays and CT scans of the chest or abdomen are taken to identify any abnormalities, such as fluid collections, thickening of tissue, or growths, that may indicate...